SenoRx Inc., an Aliso Viejo medical device maker, is poised to go public next week.
SenoRx plans to sell 5.5 million shares of its stock under the ticker “SENO.” The company could raise $60.5 million to $72 million at the high end. The company could have a market value of up to $200 million.
Banc of America Securities LLC and SG Cowen & Co. are underwriters. The company is going to use the proceeds for sales, marketing, research and development.
SenoRx’s lead product, EnCor, allows doctors to obtain multiple breast biopsy samples through a single-probe insertio.
The company received regulatory clearance for it in 2004 and started selling it last November.
SenoRx, which lost $9 million on revenue of $20 million in the 12-month period ended in March 2006, filed to go public last spring.
The company was started in 1998 and was known as BiopSolation Medical before changing its name. It has 122 workers.
